Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 September 2020Website:
http://greenwichlifesciences.comNext earnings report:
21 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 23:14:12 GMTDividend
Analysts recommendations
Institutional Ownership
GLSI Latest News
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list of additions updated as of June 21, 2024.
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a purchase price of $14.30 per share in a private placement. The closing of the private placement is expected to occur on or about June 18, 2024, subject to the satisfaction of customary closing conditions.
What type of business is Greenwich LifeSciences?
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
What sector is Greenwich LifeSciences in?
Greenwich LifeSciences is in the Healthcare sector
What industry is Greenwich LifeSciences in?
Greenwich LifeSciences is in the Biotechnology industry
What country is Greenwich LifeSciences from?
Greenwich LifeSciences is headquartered in United States
When did Greenwich LifeSciences go public?
Greenwich LifeSciences initial public offering (IPO) was on 25 September 2020
What is Greenwich LifeSciences website?
https://greenwichlifesciences.com
Is Greenwich LifeSciences in the S&P 500?
No, Greenwich LifeSciences is not included in the S&P 500 index
Is Greenwich LifeSciences in the NASDAQ 100?
No, Greenwich LifeSciences is not included in the NASDAQ 100 index
Is Greenwich LifeSciences in the Dow Jones?
No, Greenwich LifeSciences is not included in the Dow Jones index
When does Greenwich LifeSciences report earnings?
The next expected earnings date for Greenwich LifeSciences is 21 August 2024